Aptose Biosciences Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Operating expenses:
Research and development, related party
Research and development
General and administrative
Total operating expenses
Other income (expenses):
Interest income
Interest expense, related party
Change in fair value of warrants
Foreign exchange loss
Total other (expenses) income
Net loss and comprehensive loss
Unrealized gain on available-for-sale securities
Total comprehensive loss
Basic and diluted loss per common share (in dollars per share)
Basic and diluted loss per common share (in shares)
Net loss per common share, basic
Net loss per common share, diluted
Weighted-average number of common shares outstanding, basic
Weighted-average number of common shares outstanding, diluted

Comments